References
- Blumberg H., Dayton H. B., George M., Rappaport D. N. N-Allynoroxymorphine: A potent narcotic antagonist. Fed. Proc. 1961; 20: 311
- Fink M., Zaks A., Sharoff R., Mora A., Bruner A., Levit S., Freedman A. M. Naloxone in heroin dependence. Clin. Pharmacol. Therap. 1968; 2: 568–577
- Fraser H. F., Rosenberg D. E. Comparative effects of (I) chronic administration of cyclazocine, (II) substitution of nalorphine for cyclazocine, and (III) chronic administration of morphine: Pilot crossover study. Intern. J. Addictions 1966; 1: 86–98
- Freedman A. M., Fink M., Sharoff R., Zaks A. Clinical studies of cyclazocine in the treatment of narcotic addiction. Amer. J. Psychiat. 1968; 24: 1499–1504
- Jaffe J. H., Brill L. Cyclazocine, a long-acting narcotic antagonist: Its voluntary acceptance as a treatment modality in narcotic abusers. Intern. J. Addictions 1966; 1: 99–123
- Jasinski D. R., Martin W. R., Haertzen C. A. The human pharmacology and abuse potential of N-allylnoroxymorphine (Naloxone). J. Pharmacol. Exp. Therap. 1967; 157: 420–426
- Martin W. R., Grodetsky C. W., McLane T. K. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Therap. 1966; 7: 455–465
- Sadove M. S., Balagot R. C., Hatano S., Jobgen E. A. Study of N- allylnoroxymorphine—A narcotic antagonist. J. Amer. Med. Assoc. 1962; 180: 771
- Zaks A., Jones T., Fink M., Freedman A. M. Naloxone treatment of opiate dependence: A progress report. J. Amer. Med. Assoc. 1971; 215: 2108–2110